drugset / Trial / NCT06063109

A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.

NCT06063109

Phase 1 Completed 51 enrolled THPharm Corp.
RandomizedParallel-groupOpen-labelTreatment

Summary

The study was designed to evaluate the safety and pharmacokinetic interaction between THP-00101 and THP-00102 in healthy adult volunteers.

Timeline

Start
2023-10-09
Primary completion
2023-11-09
Completion
2023-11-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject Telmisartan Other / unclassified 80 mg Oral